Loading...
XFRA
VSC
Market cap28mUSD
May 02, Last price  
2.50EUR
Name

4Sc AG

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
83.17
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.53%
Rev. gr., 5y
-40.78%
Revenues
304k
-30.28%
4,353,0004,904,0007,055,0002,296,0002,060,0004,197,0004,173,0002,196,0002,252,00014,109,000436,000304,000
Net income
-8m
L-42.64%
-13,217,000-10,525,000-9,696,000-8,228,000-11,355,000-10,960,000-17,659,000-13,962,000-18,988,000-9,628,000-14,361,000-8,237,000
CFO
-10m
L+1.76%
-15,174,000-6,986,000-8,372,000-8,958,000-12,922,000-8,541,000-16,161,999-12,698,000-15,688,000-12,069,000-9,383,000-9,548,000

Profile

4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
URL
https://www.4sc.de
IPO date
Feb 25, 2008
Employees
33
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
304
-30.28%
436
-96.91%
Cost of revenue
95
155
Unusual Expense (Income)
NOPBT
209
281
NOPBT Margin
68.75%
64.45%
Operating Taxes
15
682
Tax Rate
7.18%
242.70%
NOPAT
194
(401)
Net income
(8,237)
-42.64%
(14,361)
49.16%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
3,102
Deferred revenue
Other long-term liabilities
Net debt
(5,219)
(14,825)
Cash flow
Cash from operating activities
(9,548)
(9,383)
CAPEX
(2)
(3)
Cash from investing activities
47
104
Cash from financing activities
3,000
FCF
398
(173)
Balance
Cash
8,321
14,825
Long term investments
Excess cash
8,306
14,803
Stockholders' equity
(234,494)
(226,257)
Invested Capital
242,648
239,546
ROIC
0.08%
ROCE
2.56%
2.11%
EV
Common stock shares outstanding
10,114
10,113
Price
8.85
575.57%
1.31
-62.68%
Market cap
89,509
575.61%
13,249
-62.76%
EV
84,290
(1,576)
EBITDA
740
901
EV/EBITDA
113.91
Interest
682
Interest/NOPBT
242.70%